Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.
about
Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckA Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen SecretionThe woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infectionAntiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.Clevudine inhibits hepatitis delta virus viremia: a pilot study of chronically infected woodchucks.Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.Emerging drugs for hepatitis B.Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral loadForty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized studyEmerging treatments in chronic hepatitis B.Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein.Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity.A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.MicroRNAs in Liver Health and DiseaseChronic hepatitis B: what should be the goal for new therapies?Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model.Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model.Design of therapeutic vaccines: hepatitis B as an example.Therapeutic vaccination and novel strategies to treat chronic HBV infection.New therapeutic vaccination strategies for the treatment of chronic hepatitis B.The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.Research progress of therapeutic vaccines for treating chronic hepatitis B.Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck.Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells.Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks.Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.The woodchuck hepatitis B virus infection model for the evaluation of HBV therapies and vaccine therapies.Interferon-gamma-associated responses to woodchuck hepatitis virus infection in neonatal woodchucks and virus-infected hepatocytes.Luteolin-7-O-Glucoside Present in Lettuce Extracts Inhibits Hepatitis B Surface Antigen Production and Viral Replication by Human Hepatoma Cells in Vitro.Clevudine: a promising therapy for the treatment of chronic hepatitis B
P2860
Q26828598-2D3AC234-42F0-4E44-87C7-2C282F31AD5BQ27484471-623DC5BD-EFCD-43D5-995D-7E7FEBFE0B0EQ33787525-0518E018-EC9B-4FD6-8C42-AB0EB2D1DB90Q33883722-39CAE0CE-4090-4A49-9C0E-0AC3CCBF52EAQ34077043-BC2A06A1-9642-4ACD-8C36-90C69DFAE7B9Q35171063-FC496EB4-5E68-4065-A24A-16E385FB2026Q35359369-112753E4-2BDE-4C56-BB41-572818635ACEQ35574310-EDD9507C-D46D-48D4-90C6-6E0AFABA998FQ35833000-336CFE39-1535-476B-9F7F-985F68B8A944Q35967369-63EAFEAC-BDD3-43D9-8950-FFBE0CBB023BQ36007344-96A8B621-2BCE-40E0-802D-4ED60FF8D963Q36094811-AB132A00-016E-4E8F-84A8-A143CF683378Q36099102-F871B993-46F2-4ADA-935A-19CD3B76132FQ36422622-2F308BCA-E9A6-4153-9719-E324F5729DE7Q36607090-F45F0E96-D95B-437C-BE42-53BDCFA4B636Q36607389-AC4B9F3F-30F1-4E9A-BA05-AFCEDA9BA4EFQ36739805-A89A9859-5267-4A45-BC1D-A7B360964C16Q36769986-5F753CB9-43B6-4B5F-AFC9-E93D27EE6C08Q36821357-B7B5207C-23D6-4F33-B255-28E0027EC480Q36932959-1ECFBA9D-A3B7-46FE-AB44-090B293B1D52Q36980731-C3C0BB08-55B0-4A6C-BA40-5B5FDF62A5BCQ37274697-55E169C4-5B35-4E28-AF66-79D42B51ED21Q37611862-4055C9BA-F10E-47EB-964A-B19DA0152186Q38180981-6B6EBC56-9292-433A-8637-EE36075F0DADQ38618869-42A3BE87-24AE-4E45-8CE9-6820B2F990DAQ39101021-411CF20D-CBD4-4DC4-8576-509AC540CC60Q41218508-820AB8B5-614B-4573-AD46-06814A1A313BQ42242795-3FC26084-5940-46EC-AD54-C449C86D69A5Q42416375-5643C47E-EF76-47C2-B895-FD66A84EE0DCQ42732085-916F667C-BEAD-4710-B713-19B391A6AE88Q43064406-F461D47A-9DA4-4972-A405-EED013F47960Q45356038-886039CA-CB05-423C-8F51-3CB17DEDC939Q45591313-3E24F425-981B-420D-A011-3590D72A6761Q47107633-E9666191-A7F5-43EF-A44D-D27F26AF2F1AQ57211211-12CAADE3-55DA-420D-8851-5744E33ADFF5
P2860
Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunization with surface antigen vaccine alone and after treatment with 1-
@nl
Immunization with surface anti ...... uck hepatitis virus infection.
@ast
Immunization with surface anti ...... uck hepatitis virus infection.
@en
type
label
Immunization with surface antigen vaccine alone and after treatment with 1-
@nl
Immunization with surface anti ...... uck hepatitis virus infection.
@ast
Immunization with surface anti ...... uck hepatitis virus infection.
@en
prefLabel
Immunization with surface antigen vaccine alone and after treatment with 1-
@nl
Immunization with surface anti ...... uck hepatitis virus infection.
@ast
Immunization with surface anti ...... uck hepatitis virus infection.
@en
P2093
P2860
P1433
P1476
Immunization with surface anti ...... uck hepatitis virus infection.
@en
P2093
Brent E Korba
Bud C Tennant
Carol A Roneker
John L Gerin
Paul J Cote
Stephan Menne
P2860
P304
P356
10.1128/JVI.76.11.5305-5314.2002
P407
P577
2002-06-01T00:00:00Z